DocGo Explores Strategic Alternatives, Raises 2026 Guidance Despite Large 2025 Net Loss
DCGO sits 21% above its 52-week low of $0.597 on elevated volume (1.9× avg).
Summary
DocGo Inc. announced a formal process to explore strategic alternatives to maximize shareholder value, alongside reporting a significant net loss for 2025 driven by non-cash impairments, but also raised its 2026 revenue and adjusted EBITDA guidance.
Key Events · Corporate Governance and Compliance · DCGO
-
Initiated Strategic Alternatives Process
DocGo Inc. has commenced a formal process to explore strategic alternatives to maximize shareholder value, indicating potential for significant corporate changes.
-
Raised 2026 Financial Guidance
The company increased its full-year 2026 revenue guidance to $290-$310 million (from $280-$300 million) and narrowed its adjusted EBITDA loss expectation to $5-$10 million (from $15-$25 million loss).
-
Reported Significant 2025 Net Loss
DocGo reported a net loss of $196.4 million for the full year 2025, compared to a net income of $13.4 million in 2024. This loss included $93.8 million in non-cash impairments (goodwill, intangible assets, equity investment).
-
Strong Core Business Growth
The 'healthcare at any address' business tripled its revenue in Q4 2025, and the company achieved record volumes across its US medical transportation, healthcare in the home, mobile phlebotomy, remote patient monitoring, and virtual care & lab orders business lines.
Analysis · DCGO · Industrial Applications And Services
DocGo Inc. has initiated a formal process to explore strategic alternatives aimed at maximizing shareholder value. This is a highly significant development for the company, suggesting potential transformative changes such as a sale, merger, or major restructuring. The announcement comes alongside mixed financial results for 2025, which saw a substantial net loss of $196.4 million, largely due to non-cash impairments totaling $93.8 million and the wind-down of migrant-related programs. However, the company also reported strong growth in its core 'healthcare at any address' business, which tripled in Q4 2025, and raised its full-year 2026 revenue and adjusted EBITDA guidance. Investors will closely monitor the progress of the strategic alternatives review and the company's ability to execute on its improved 2026 outlook, particularly achieving profitability in the second half of the year as projected by management.
At the time of this filing, DCGO was trading at $0.72 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $63.3M. The 52-week trading range was $0.60 to $3.00. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.